Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04233749 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 9, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Dec 30, 2024 to Dec 30, 2025
    • Site contact updated
    v7
  2. Primary completion date: Mar 30, 2024 to Dec 30, 2024v6
  3. Re-verified, no change to tracked fieldsv5
  4. Primary completion date: Mar 30, 2023 to Mar 30, 2024
    • Study completion date: Jan 30, 2024 to Dec 30, 2024
    v4
  5. Phase: Not applicable to Phase 2
    • Primary completion date: Mar 30, 2021 to Mar 30, 2023
    • Study completion date: May 30, 2021 to Jan 30, 2024
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 30, 2020 to Mar 17, 2020
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.
Trial Details
NCT Number NCT04233749
Lead Sponsor Henry Ford Health System
Conditions
(from sponsor)		 Lichen Planus Pigmentosus, Erythema Dyschromicum Perstans, Ashy Dermatosis of Ramirez
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov